- |||||||||| Halaven (eribulin mesylate) / Eisai, Nexavar (sorafenib) / Bayer, Amgen
Clinical, P1 data, Journal, Combination therapy: Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors. (Pubmed Central) - Apr 30, 2019 The combination of sorafenib and eribulin mesylate presented no unexpected safety concerns and no significant impact on QT/QTc intervals or drug-drug interactions. Sorafenib 400 mg BID plus standard-dose eribulin is the RP2D.
- |||||||||| Lartruvo (olaratumab) / Eli Lilly, Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Clinical, Journal: Soft tissue sarcomas in the precision medicine era: new advances in clinical practice and future perspectives. (Pubmed Central) - Apr 28, 2019 Several treatments have been recently developed with the specific aim of targeting different cell pathways and immune-checkpoints that have been recognized to drive tumour progression. The following attempts to provide a review of literature focusing on the available data concerning novel treatments and future prospective for the management of metastatic STSs.
- |||||||||| Avastin (bevacizumab) / Roche
Journal: Cutaneous angiosarcoma: update on biology and latest treatment. (Pubmed Central) - Apr 26, 2019 The following attempts to provide a review of literature focusing on the available data concerning novel treatments and future prospective for the management of metastatic STSs. Future research efforts should focus on the following aspects of cAS: drug development directed at recent molecular targets, clinical trials designed specifically for patients with cAS, and the role of immunotherapy for cAS.
- |||||||||| doxorubicin hydrochloride / generics
Review, Journal: The challenge of finding new therapeutic avenues in soft tissue sarcomas. (Pubmed Central) - Apr 23, 2019 However, new therapeutic avenues including new drug developments and registrations such as trabectedin, pazopanib and eribulin as well as numerous clinical trial options have recently enriched the therapeutic armamentarium in the treatment of patients with advanced soft tissue sarcomas. The challenges and pitfalls of finding such new therapeutic avenues in recent years for the treatment benefit of patients with soft tissue sarcomas will be presented in this chapter within the thematic series on "Challenges in Sarcoma".
- |||||||||| Halaven (eribulin mesylate) / Eisai
Clinical, Journal: Active substances from marine organisms in clinical trials and practice (Pubmed Central) - Apr 19, 2019 Although just a few of them are used in a clinical practice today (e.g. eribulin, cytarabine), the future looks quite promising. Current clinical trials focus mostly on the therapy of cancer, but trials for therapy of pain or Alzheimers disease and many others are also underway.Key words: marine pharmacology.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Halaven (eribulin mesylate) / Eisai
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: KELLY: Ph II Study of Pembrolizumab & Eribulin in Patients With HR+/HER2- MBC Previously Treated With Anthracyclines & Taxanes (clinicaltrials.gov) - Apr 18, 2019 P2, N=44, Active, not recruiting, Current clinical trials focus mostly on the therapy of cancer, but trials for therapy of pain or Alzheimers disease and many others are also underway.Key words: marine pharmacology. Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Oct 2020 | Trial primary completion date: Aug 2019 --> Oct 2018
- |||||||||| Halaven (eribulin mesylate) / Eisai, Imfinzi (durvalumab) / AstraZeneca
Enrollment closed, Combination therapy, Metastases: Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer (clinicaltrials.gov) - Apr 17, 2019 P1, N=12, Active, not recruiting, Recruiting --> Active, not recruiting | Trial completion date: Aug 2019 --> Oct 2020 | Trial primary completion date: Aug 2019 --> Oct 2018 Recruiting --> Active, not recruiting
- |||||||||| Halaven (eribulin mesylate) / Eisai
Clinical, Journal: Radiotherapy and Eribulin Mesylate for Mediastinal Node Metastasis from Breast Cancer-A Case Report (Pubmed Central) - Apr 13, 2019 ...She was treated with neoadjuvant chemotherapy( AC followed by paclitaxel)and followed up with left total mastectomy with axillary lymphadenectomy for breast cancer(pT3N1aM0, Stage â…¢A, ER positive, PgR positive, and HER2 negative)...We changed the regimen to capecitabine...After the radiotherapy, chest CT revealed a remarkable reduction of lymph node size and full pulmonary reexpansion. One year after the radiotherapy, she is continuing treatment without systemic progression.
- |||||||||| balixafortide (POL 6326) / Polyphor, Halaven (eribulin mesylate) / Eisai
P1 data, Journal: Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. (Pubmed Central) - Apr 11, 2019 P1 The safety and tolerability of balixafortide plus eribulin seems to be similar to that of eribulin or balixafortide monotherapy, and the preliminary activity of the combination seems promising in patients with HER-negative metastatic breast cancer. The results suggest that balixafortide plus eribulin has potential to provide a new therapeutic option in heavily pretreated patients with metastatic breast cancer and warrants further investigation in randomised trials.
- |||||||||| Yondelis (trabectedin) / J&J, Otsuka, PharmaMar, Votrient (pazopanib) / Novartis, Halaven (eribulin mesylate) / Eisai
Review, Journal: Therapeutic Targets for Bone and Soft-Tissue Sarcomas. (Pubmed Central) - Apr 9, 2019 Based on these basic studies, new anticancer drugs, including pazopanib, trabectedin, eribulin, and immune checkpoint inhibitors have been developed and the efficacies and safety of the new drugs have been assessed by clinical trials. This review summarizes new molecular therapeutic targets and advances in the treatment for bone and soft tissue sarcomas.
- |||||||||| Halaven (eribulin mesylate) / Eisai, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Eribulin and Lenvatinib in Advanced Solid Tumors (clinicaltrials.gov) - Apr 8, 2019 P2, N=32, Active, not recruiting, This review summarizes new molecular therapeutic targets and advances in the treatment for bone and soft tissue sarcomas. Recruiting --> Active, not recruiting | Trial completion date: Mar 2019 --> Dec 2020 | Trial primary completion date: Mar 2019 --> Dec 2019
- |||||||||| Halaven (eribulin mesylate) / Eisai
Journal: Tumour lysis syndrome following eribulin for metastatic uterine leiomyosarcoma. (Pubmed Central) - Apr 5, 2019 She elected treatment with palliative eribulin, presenting with acute renal failure and electrolyte abnormalities consistent with tumour lysis syndrome on cycle 1 day 8. Despite aggressive supportive care and treatment including intravenous hydration, bicarbonate and rasburicase, she continued to decline, ultimately foregoing haemodialysis in favour of palliative care and passed away in the hospital.
- |||||||||| paclitaxel trevatide (ANG1005) / Angiochem
Trial completion date, Trial initiation date: ANGLeD: ANG1005 in Leptomeningeal Disease From Breast Cancer (clinicaltrials.gov) - Apr 5, 2019 P3, N=150, Not yet recruiting, Despite aggressive supportive care and treatment including intravenous hydration, bicarbonate and rasburicase, she continued to decline, ultimately foregoing haemodialysis in favour of palliative care and passed away in the hospital. Trial completion date: May 2021 --> Dec 2021 | Initiation date: Apr 2019 --> Sep 2019
- |||||||||| Ixempra (ixabepilone) - Otsuka, R / Pharm, Halaven (eribulin mesylate) / Eisai
Biomarker, Enrollment open, Trial completion date, Trial primary completion date, Biopsy: Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy (clinicaltrials.gov) - Mar 19, 2019 P=N/A, N=35, Recruiting, Furthermore, EM maintained clinical activity and a tolerable safety profile. Suspended --> Recruiting | Trial completion date: Feb 2019 --> Jun 2021 | Trial primary completion date: Feb 2019 --> Jun 2020
- |||||||||| Halaven (eribulin mesylate) / Eisai
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer (clinicaltrials.gov) - Mar 11, 2019 P4, N=200, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=83 --> 200 | Trial completion date: Jun 2019 --> Nov 2019 | Trial primary completion date: Feb 2019 --> Aug 2019
- |||||||||| Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (clinicaltrials.gov) - Mar 1, 2019
P2, N=20, Recruiting, Initiation date: Jan 2019 --> Apr 2019 Trial completion date: Jul 2020 --> Jul 2021 | Initiation date: May 2016 --> Mar 2017 | Trial primary completion date: Jul 2019 --> Jul 2020
- |||||||||| Halaven (eribulin mesylate) / Eisai
Trial completion date, Trial primary completion date: Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate (clinicaltrials.gov) - Feb 11, 2019 P2, N=9, Active, not recruiting, N=910 --> 200 | Trial completion date: Jun 2020 --> Jun 2019 | Active, not recruiting --> Suspended Trial completion date: Oct 2019 --> Jul 2020 | Trial primary completion date: Jan 2018 --> Jul 2018
- |||||||||| Halaven (eribulin mesylate) / Eisai, Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
Trial completion date, PD(L)-1 Biomarker, Metastases: Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer (clinicaltrials.gov) - Feb 8, 2019 P2, N=33, Recruiting, Trial completion date: Oct 2019 --> Jul 2020 | Trial primary completion date: Jan 2018 --> Jul 2018 Trial completion date: Aug 2021 --> Aug 2020
- |||||||||| Halaven (eribulin mesylate) / Eisai
Trial completion, Trial completion date, Trial primary completion date, Patient reported outcomes, Metastases: Eribulin in HER2 Negative Metastatic BrCa (clinicaltrials.gov) - Feb 6, 2019 P2, N=83, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial completion date: Jul 2018 --> May 2016 | Trial primary completion date: Jun 2017 --> May 2016
|